Collectively, these findings demonstrate that LIF is a critical mediator of tumor progression and immunosuppression in peritoneal carcinomatosis and may serve as a therapeutic target and prognostic biomarker in this aggressive GC subset [28]. This evidence concerns the gene LIF and gastric cancer.